Clinical trials: Tamoxifen
Hot Flashes, Breast Cancer
Study of Acupuncture in the Treatment of Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer.
This study intends to further evaluate the efficacy of acupuncture by comparing the intervention effects of different acupuncture treatment regimens on hot flashes in breast cancer ; and to explore the central effect regulation…
- Conditions
- Hot Flashes, Breast Cancer, Acupuncture
- Trial name
- NCT05613504
- Testing
- Acupuncture treatment
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Nanjing University of Traditional Chinese Medicine
Breast Cancer
Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast Cancer
In recent years, the successful application of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has transformed the treatment landscape for HR+/HER2- advanced breast cancer and driven research into their use in adjuvant settings.
- Trial name
- NCT07706933
- Testing
- Dalpiciclib, Abemaciclib/Ribociclib
- Volunteers
- 456 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer
CYP2D6 Genotyping by AmpliChipTM CYP450 for Tamoxifen-Treated Breast Cancer Patients
The aim of the study is to examine whether tamoxifen-treated Israeli breast cancer patients who are CYP2D6 poor metabolizers (CYP2D6*4/*4 genotype) are at higher cancer relapse risk during 2.5-5-year follow-up period from initial…
- Trial name
- NCT00815555
- Testing
- There is no intervention - this is an observational study
- Where
- Israel
- Volunteers
- 500 people
- Sponsor
- Assaf-Harofeh Medical Center
Cardiac Toxicity, Inflammatory Breast Cancer
Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer
Randomized phase III trial to compare the effectiveness of combination chemotherapy, surgery, and radiation therapy with or without dexrazoxane and trastuzumab in treating women who have stage IIIA, stage IIIB or stage IV breast…
- Conditions
- Cardiac Toxicity, Inflammatory Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT00016276
- Testing
- dexrazoxane hydrochloride, doxorubicin hydrochloride, cyclophosphamide
- Where
- United States
- Volunteers
- 396 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Red Clover and Lifestyle Changes to Contrast Menopausal Symptoms in Premenopausal Breast Cancer Patients Given Tamoxifen
A prospective double-blind randomized trial of red clover extract (Promensil) vs placebo in surgically-treated premenopausal women with estrogen receptor-positive breast cancer taking tamoxifen
- Trial name
- NCT03844685
- Testing
- Promensil
- Where
- Italy
- Volunteers
- 88 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Pancreatic Neoplasms
Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas
Tamoxifen for Solid Pseudopapillary Tumor of the Pancreas
- Trial name
- SPTP (NCT06914674)
- Testing
- Tamoxifen 20 mg
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Mastectomy
Selected Exercise Program on Upper Cross Syndrome Post-unilateral Mastectomy
The purpose of the study is to evaluate the therapeutic efficacy of exercise rehabilitation program on upper limb range and forward head posture post unilateral radical mastectomy.
- Trial name
- NCT07447024
- Testing
- Selected exercise program, Routine medical therapy
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
Cancer, Gastrointestinal Neoplasms
Tamoxifen in Patients With Oesophageal Cancer
Cancer of the gullet (oesophagus) is a lethal disease in which only 15% of patients survive 5 years once diagnosed. It is more common in men than women, and men appear to have a worse prognosis.
- Trial name
- NCT02513849
- Testing
- Tamoxifen
- Where
- 2 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- University of Nottingham
Breast Cancer, Invasive Breast Cancer
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
This is an exploratory interventional study that initiates standard-of-care anti-estrogen treatment preoperatively for four weeks.
- Trial name
- NCT03219476
- Testing
- Anastrozole, Letrozole, Exemestane
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Medical College of Wisconsin
Breast Cancer
Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients
This study will help to understand the interaction between estrogen receptor-alpha (ER alpha) and tumor suppressor protein p53 as well as impact on patient tumor gene expression in response to the hormonal therapy Tamoxifen.
- Trial name
- NCT01027416
- Testing
- Tamoxifen
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- Roswell Park Cancer Institute
Breast Neoplasms
Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women
The purpose of this study is to find out if the two different formulations of exemestane (Aromasin), oral and injectable, are equivalent in terms of pharmacodynamics and pharmacokinetics, i.e., if ultimately both formulations…
- Trial name
- NCT00040014
- Testing
- exemestane
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Pfizer
Breast Cancer, DCIS
Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients
In hormone-receptor positive breast cancer or DCIS (ductal carcinoma in situ) tamoxifen remains an important treatment option for patients before menopause and those patients after menopause who cannot be treated with…
- Trial name
- TAMENDOX (NCT03931928)
- Testing
- (Z)-Endoxifen supplementation according to genotype, (Z)-Endoxifen supplementation according to plasma levels
- Where
- 40 sites in Germany
- Volunteers
- 356 people
- Sponsor
- Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
Breast Neoplasm Female
Effects of Training and Detraining on Postmenopausal Breast Cancer Survivors
The present study aimed to verify the effects of resistance exercise training and successive detraining on body composition, lipid profile, muscle strength, oxidative stress, and inflammatory markers of postmenopausal breast…
- Trial name
- NCT04479098
- Testing
- Resistance exercise training, Exercise detraining
- Where
- Brazil
- Volunteers
- 14 people
- Sponsor
- Federal University of Uberlandia
Breast Neoplasms
Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients
This is a prospective, phase IIa, multicenter, randomized, open-label study comparing a pre-surgical combination of trastuzumab and pertuzumab with concurrent weekly paclitaxel chemotherapy or endocrine therapy given for 12 weeks…
- Trial name
- TP-II (NCT03272477)
- Testing
- Perjeta Injectable Product, Herceptin, Tamoxifen
- Where
- Germany
- Volunteers
- 257 people
- Sponsor
- Palleos Healthcare GmbH
Mammographically Dense Breast
Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast
This randomized phase II trial studies how well afimoxifene works in reducing the risk of breast cancer in women with mammographically dense breast. Estrogen can cause the growth of breast cancer cells.
- Trial name
- NCT03063619
- Testing
- Afimoxifene, Laboratory Biomarker Analysis, Questionnaire Administration
- Where
- 5 sites in United States
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Breast Neoplasms
Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer
This non-interventional study will be conducted in several Eastern European countries to assess the safety, tolerability and efficacy of Aromasin® when it is administered in real-word setting in postmenopausal women with invasive…
- Trial name
- NCT01239745
- Testing
- Aromasin
- Where
- 11 sites in Croatia, Estonia and 1 more
- Volunteers
- 46 people
- Sponsor
- Pfizer
Breast Cancer
The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer
The investigators would like to study the genetic and molecular outcomes that results after a short term neoadjuvant hormonal therapy on patients with breast cancer.
- Trial name
- NCT04129216
- Testing
- Tamoxifen Citrate, Letrozole, Exemestane
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Johns Hopkins University
Brain and Central Nervous System Tumors, Metastatic Cancer
Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors
RATIONALE: Drugs used in chemotherapy, such as carboplatin and topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00541138
- Testing
- carboplatin, tamoxifen citrate, topotecan hydrochloride
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- City of Hope Medical Center
Breast Cancer, Metastasis
A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer
The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Nolvadex (tamoxifen) as first-line treatment for postmenopausal women with advanced breast cancer.
- Trial name
- NCT00241449
- Testing
- Fulvestrant, Tamoxifen
- Where
- 139 sites in United States, Argentina and 24 more
- Volunteers
- 51 people
- Sponsor
- AstraZeneca
Breast Cancer
Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer
The purpose of this study is to examine the efficacy and safety as well as the characteristics of the female hormone and study medications after administration in pre-menopausal women with estrogen receptor positive advanced…
- Trial name
- NCT01073865
- Testing
- ZD9393 (Zoladex) 10.8 mg, ZD9393 (Zoladex) 3.6 mg
- Where
- 55 sites in India, Japan and 4 more
- Volunteers
- 222 people
- Sponsor
- AstraZeneca